Inceptor Bio Appoints Matthias Schroff, PhD, as Chief Executive Officer

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, announced the appointment of Dr. Matthias Schroff as CEO effective today. Dr. Schroff will also join the Board of Directors. Dr. Schroff succeeds Mr. Shailesh Maingi, who will remain as Executive Chairman. Dr. Schroff has extensive biopharmaceutical leadership experience with a track record […]

Ori Biotech and Inceptor Bio Partner to Accelerate Solid tumor Cell Therapy Access

Inceptor joins Ori’s LightSpeed Early Access Program (LEAP) to future proof manufacturing capabilities, ahead of its first clinical trials in 2024 Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technologies, and Inceptor Bio, a next-gen cell therapy biotechnology company, have announced a new partnership to utilize Ori Biotech’s manufacturing platform technology and […]

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors. Under the agreement, Inceptor will utilize Avectas’ SOLUPORE® technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell […]

Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel IPSC Platform

Morrisville, NC – June 30, 2022 – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota. The aim of this collaboration is to build a novel induced pluripotent stem cells (iPSC) platform that will accelerate Inceptor Bio’s best-in-class next-generation cell therapies platforms. Under the terms of the […]

Inceptor Bio Announces $37 Million Series A Financing

Morrisville, NC – May 19, 2022 – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures. Proceeds from the Series A financing will be used to advance Inceptor Bio’s CAR-T lead program to a Phase I clinical trial […]

Inceptor Bio Enters into In-Licensing Agreement for CAR-M Platform

RALEIGH, N.C., Dec. 16, 2021 /PRNewswire/ — Inceptor Bio, a Research Triangle Park-based next-generation cell and gene therapy biotechnology company, today announced that it has executed an in-licensing agreement with the University of California, Santa Barbara (UCSB) for an investigational Chimeric Antigen Receptor Macrophage (CAR-M) therapy targeting difficult-to-treat tumors. “This strategic alliance is an important step in advancing Inceptor Bio’s next-generation cell […]

Inceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility and Transfer Operating Team from Arranta Bio

Inceptor Bio (“Inceptor”), today announced an agreement with Arranta Bio (“Arranta”) for the acquisition of a 29,000 ft2 process development and GMP clinical manufacturing facility and the transfer of a core operating team to establish cell therapy processes and clinical supply for Inceptor Bio’s planned oncology clinical trials. Inceptor Bio’s Advanced Manufacturing Platform (AMP+) will be […]

Inceptor Bio Launches Next-Generation CAR-T, CAR-M, and NK/NKT Platform Focused on Advancing Cell and Gene Therapies to Cure Difficult-to-Treat Cancers

— Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment (TME). — Inceptor Bio was established to pursue a diversified cell therapy portfolio with ‘differentiation that matters’ across multiple cell types including CAR-T, CAR-macrophage (CAR-M) and […]